Vogenx (NASDAQ:VOGX) Stock Moved Up to Hold by Zacks Research

Zacks Research upgraded shares of Vogenx (NASDAQ:VOGX) to a hold rating in a research report sent to investors on Monday morning,Zacks reports.

Several other research firms have also weighed in on VOGX. JonesTrading started coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 target price on the stock. Wall Street Zen raised Vogenx to a “hold” rating in a research report on Saturday, August 22nd. Finally, WBB Securities assumed coverage on Vogenx in a research report on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $48.50.

Vogenx Trading Up 10.5%

Shares of VOGX opened at $24.32 on Monday. Vogenx has a 12 month low of $12.95 and a 12 month high of $38.41.

Vogenx (NASDAQ:VOGX) last released its quarterly earnings results on Thursday, September 17th. The company reported ($0.07) earnings per share for the quarter. As a group, equities research analysts forecast that Vogenx will post -0.61 earnings per share for the current year.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.